Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 5:33 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 433–456 of 2,098 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Chronic Lung Disease Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Single Centre Randomized Study Evaluating The Safety And Tolerability Of GSK233705 In Healthy Volunteers.

NCT00453687
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
GSK233705
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 7, 2017 · Synced Oct 14, 2026, 5:33 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Hypoxia and Heart Rate Variability

NCT05606406
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive, Hypoxia
Interventions
Nocturnal Oxygen
Other
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Oct 14, 2026, 5:33 PM EDT
Completed Phase 4 Interventional

ADVAIR® DISKUS® Inhaler (Fluticasone Propionate/Salmeterol) Versus SEREVENT® DISKUS® Inhaler (Salmeterol) For The Treatment Of Chronic Obstructive Pulmonary Disease Exacerbations. ADVAIR® DISKUS® Inhaler and SEREVENT® DISKUS® Inhaler Are Trademarks of the GSK Group of Companies.

NCT00144911
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Salmeterol, Fluticasone Propionate/Salmeterol Combination Product
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
740 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
85
States / cities
Birmingham, Alabama • Jasper, Alabama • Glendale, Arizona + 78 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2016 · Synced Oct 14, 2026, 5:33 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Airvo 3 Respiratory Rate Validation Study

NCT06329609
View directory record Official record
Conditions
COPD, Healthy Volunteers
Interventions
Airvo 3 with respiratory rate algorithm
Device
Lead sponsor
Fisher and Paykel Healthcare
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Louisville, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 26, 2024 · Synced Oct 14, 2026, 5:33 PM EDT
Completed No phase listed Observational

Replication of the IMPACT COPD Trial in Healthcare Claims Data

NCT05062304
View directory record Official record
Conditions
COPD
Interventions
Fluticasone Furoate-Vilanterol Trifenatate, Furoate-umeclidinium-vilanterol
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
40 Years to 120 Years
Enrollment
17,281 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 27, 2023 · Synced Oct 14, 2026, 5:33 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Palliative Care Health Literacy Education and QOL Compared to Usual Care

NCT06089499
View directory record Official record
Conditions
COPD
Interventions
Get Palliative Care: four educational learning module videos
Behavioral
Lead sponsor
University of Missouri, Kansas City
Other
Eligibility
65 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 18, 2023 · Synced Oct 14, 2026, 5:33 PM EDT
Active, not recruiting Phase 1 Interventional

Leflunomide in Treating Patients With Steroid Dependent Chronic Graft Versus Host Disease

NCT04212416
View directory record Official record
Conditions
Chronic Graft Versus Host Disease, Steroid Refractory Graft Versus Host Disease
Interventions
Leflunomide
Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Oct 14, 2026, 5:33 PM EDT
Completed Phase 2 Interventional

Study in Patients With COPD

NCT00215384
View directory record Official record
Conditions
COPD
Interventions
Formoterol Fumarate
Drug
Lead sponsor
Dey
Industry
Eligibility
50 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2005
U.S. locations
7
States / cities
Los Angeles, California • Upland, California • Denver, Colorado + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 11, 2010 · Synced Oct 14, 2026, 5:33 PM EDT
Completed Phase 3 Interventional

To Evaluate the Long-term Safety of (R,R)-Formoterol in Subjects With COPD

NCT00064415
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, Chronic Bronchitis, Emphysema
Interventions
arformoterol, Salmeterol
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
35 Years and older
Enrollment
799 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
90
States / cities
Anniston, Alabama • Birmingham, Alabama • Jasper, Alabama + 77 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2012 · Synced Oct 14, 2026, 5:33 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

A Prospective Observational Study of the Breath Responsive Variable Bolus Oxygen Conserving Device

NCT02627599
View directory record Official record
Conditions
COPD
Interventions
Breath Responsive Variable Bolus Oxygen Conserving Device
Device
Lead sponsor
StratiHealth
Industry
Eligibility
65 Years to 85 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
3
States / cities
Oceanside, California • Vista, California • Westminster, California
Source: ClinicalTrials.gov public record
Updated Aug 15, 2018 · Synced Oct 14, 2026, 5:33 PM EDT
Completed Phase 2 Interventional

Pilot Study of the Spiration IBV™ System

NCT00145548
View directory record Official record
Conditions
Emphysema
Interventions
Intra Bronchial Valve
Device
Lead sponsor
Olympus Corporation of the Americas
Industry
Eligibility
18 Years to 70 Years
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
14
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2011 · Synced Oct 14, 2026, 5:33 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Effect of Inhaled Steroids on Gene Expression in the Lungs - 2

NCT00826748
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
Beclomethasone
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 25, 2018 · Synced Oct 14, 2026, 5:33 PM EDT
Terminated Phase 1 Interventional

Upfront Ruxolitinib for Chronic Graft-vs-host Disease

NCT06695507
View directory record Official record
Conditions
Chronic Graft Versus Host Disease
Interventions
Ruxolitinib
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
12 Years to 30 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 25, 2026 · Synced Oct 14, 2026, 5:33 PM EDT
Terminated Not applicable Interventional Results available

The Use of High Frequency Oscillations With NIV in Hypercapnic COPD Participants

NCT02680639
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
BiPAP Synchrony ventilator
Device
Lead sponsor
Philips Respironics
Industry
Eligibility
21 Years to 85 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 6, 2019 · Synced Oct 14, 2026, 5:33 PM EDT
Completed No phase listed Observational

Neurotrophin Expression in Infants as a Predictor of Respiratory and Neurodevelopmental Outcomes

NCT03373539
View directory record Official record
Conditions
Bronchopulmonary Dysplasia, Chronic Lung Disease
Interventions
Not listed
Lead sponsor
The Cleveland Clinic
Other
Eligibility
1 Day to 4 Months
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 26, 2025 · Synced Oct 14, 2026, 5:33 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Emphysema Research Registry and Biosample Repository

NCT00307281
View directory record Official record
Conditions
Emphysema, Chronic Obstructive Pulmonary Disease, Chronic Bronchitis
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
21 Years and older
Enrollment
3,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2030
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 14, 2026, 5:33 PM EDT
Withdrawn Phase 4 Interventional

Macitentan in the Treatment of Organ Rejection After Lung Transplantation

NCT02893176
View directory record Official record
Conditions
Lung Transplant Rejection
Interventions
macitentan, placebo (for macitentan)
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
21 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 11, 2020 · Synced Oct 14, 2026, 5:33 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Imaging Lung Function Using Oxygen Enhanced MRI

NCT01731015
View directory record Official record
Conditions
COPD, Asthma, Cystic Fibrosis, Emphysema, Small Airways Disease
Interventions
Medical Grade Oxygen
Drug
Lead sponsor
Hal C Charles
Other
Eligibility
18 Years to 90 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 22, 2014 · Synced Oct 14, 2026, 5:33 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Trial of 12 Weeks of Treatment With Nebulized SUN-101 in Patients With COPD (GOLDEN-4)

NCT02347774
View directory record Official record
Conditions
COPD, Chronic Obstructive Pulmonary Disease
Interventions
SUN-101 50 mcg BID eFlow (CS) nebulizer, SUN-101 25 mcg BID eFlow (CS) nebulizer, Placebo eFlow (CS) nebulizer
Drug
Lead sponsor
Sunovion Respiratory Development Inc.
Industry
Eligibility
40 Years and older
Enrollment
641 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
45
States / cities
Andalusia, Alabama • Jasper, Alabama • Glendale, Arizona + 40 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2018 · Synced Oct 14, 2026, 5:33 PM EDT
Completed No phase listed Observational

Ancillary T Cell Based Studies in SPIROMICS

NCT02036190
View directory record Official record
Conditions
Smoke Induced Lung Disease
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
40 Years to 80 Years
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 3, 2016 · Synced Oct 14, 2026, 5:33 PM EDT
Recruiting Phase 2 Interventional

Axatilimab for Sclerotic Chronic Graft-versus-Host Disease

NCT07011810
View directory record Official record
Conditions
Chronic Graft Versus Host Disease
Interventions
Axatilimab, Biospecimen Collection, Questionnaire Administration, Skin Biopsy, Skin Measurement
Biological · Procedure · Other
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
3
States / cities
Tampa, Florida • Boston, Massachusetts • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 14, 2026, 5:33 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy of Multiple Doses of QAX028 in Chronic Obstructive Pulmonary Disease (COPD) Patients

NCT01068613
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
QAX028, Tiotropium, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
4
States / cities
Anaheim, California • Normal, Illinois • Spartanburg, South Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2020 · Synced Oct 14, 2026, 5:33 PM EDT
Completed Phase 3 Interventional

Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations.

NCT05158387
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
Tozorakimab, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years to 130 Years
Enrollment
1,172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
34
States / cities
Sheffield, Alabama • Lincoln, California • Newport Beach, California + 31 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Oct 14, 2026, 5:33 PM EDT
Completed Phase 1Phase 2 Interventional

Addition of ISIS 14803 to Therapy With Peginterferon and Ribavirin for Chronic Hepatitis C (HCV) Patients Not Responding Adequately to the Two Drugs

NCT00062816
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
ISIS 14803, peginterferon alfa, ribavirin
Drug
Lead sponsor
Ionis Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
25
States / cities
Birmingham, Alabama • Phoenix, Arizona • Orange, California + 22 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2022 · Synced Oct 14, 2026, 5:33 PM EDT